This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device.
The Endocrine Society recommends against screening for testosterone deficiency for the general population.6 However, serum testosterone should be measured in patients who show signs of testosterone deficiency.6
Androderm® is an androgen indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
IMPORTANT SAFETY INFORMATION
Androderm® should not be used in men with carcinoma of the breast, known or suspected carcinoma of the prostate, or patients with pre-existing cardiac, renal, or hepatic disease. Androderm® should also not be used in pregnant or breastfeeding women, as testosterone may cause fetal harm. Patients with benign prostatic hyperplasia (BPH) should be monitored for worsening signs and symptoms, and exposure of Androderm® to women or children should be avoided. Exogenous administration of testosterone may lead to azoospermia, and sleep apnea may occur in those with risk factors. Patients should be monitored for prostate specific antigen (PSA), liver function, lipid concentrations, hematocrit, and hemoglobin. In a clinical study of 36 patients treated with Androderm®, skin irritation from the patch was the most common adverse event (pruritus at application site [17%]), followed by application site vesicles (6%), and back pain (6%).
Please see full Prescribing Information.
Models are for illustrative purposes only.